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Background: The TP73 and TP63 genes are members of the p53
tumor suppressor family and are expressed in different N-terminal
isoforms either with proapoptotic (transactivation domain, TA) and
antiapoptotic (N-terminally truncated, N) function. Unlike p53, the
role of p73 and p63 in tumor is controversial. It has been recently
hypothesized that altered N:TA expression ratio, rather than single
isoform overexpression, plays a role in the pathogenesis of many
diseases, including lung cancer.
Methods: Isoform-specific, real-time polymerase chain reaction and
immunohistochemistry analysis on matched cancer and correspond-
ing normal tissues from surgically resected non-small cell lung
cancers (NSCLCs) have been performed aiming to explore the
expression levels of each p63 and p73 N-terminal isoforms and their
N:TA expression ratio.
Results: For both p63 and p73, a N-terminal isoform-specific
modulation that alter N:TA isoform balance was identified. In
particular, Np63 isoform was significantly up-modulated, whereas
TAp63 was slightly down-modulated in NSCLC specimens. Like-
wise, 2p73 and 2/3p73 were up-modulated, whereas Np73 and
Np73 isoforms were down-modulated. Moreover, a higher TAp63
and Np73 transcripts expression, detected in the normal tissue
surrounding the tumors, correlates with poor patient outcome, rep-
resenting independent prognostic factors for overall survival
(Np73: p  0.049, hazard ratio  3.091, 95% confidence inter-
val  1.005–9.524 and TAp63: p  0.001, hazard ratio  8.091,
95% confidence interval  2.254–29.05).
Conclusion: Our findings suggest that p63 and p73 altered N:TA
expression ratio occurs in NSCLC likely contributing to the molec-
ular pathogenesis of this tumor.
Key Words: p63, p73, Isoform, Quantitative PCR, Immunohisto-
chemistry, Molecular marker, Non-small cell lung cancer.
(J Thorac Oncol. 2011;6: 473–481)
The tumor suppressor p53 is a key transcription factorregulating the expression of genes influencing cell senes-
cence, proliferation, apoptosis, and differentiation. The TP73
and TP63 genes are members of the p53 tumor suppressor
family, based on substantial structural and functional homol-
ogies. Unlike p53, that is a tumor suppressor, the role of p73
and p63 in tumor is controversial because of their genomic
locus complexity. Through either alternative exon splicing, or
a second promoter, TP73 and TP63 genes generate several N-
and C-terminal isoforms. The N-terminal isoforms can be
clustered into two groups: the transactivation competent TA
proteins (TAp63 and TAp73) and the transactivation-defec-
tive, N-terminally truncated N proteins (Np63, Np73,
2p73, 2/3p73, and Np73).1 TAp63 and TAp73, and p53,
transactivate genes that promote either cell cycle arrest or
apoptosis.2,3 Conversely, N isoforms act as dominant negative
inhibitors of TA counterparts and p53 functions and in turn
hamper apoptosis.2,3 Different p63 and p73 N-terminal isoform
expression ratio triggers proproliferative and antiproliferative
signals important for cell fate and normal cell cycling, senes-
cence, or apoptosis decision making. Therefore, these regula-
tions could be affected on neoplastic transformation.4
Mutations within the p53 gene are the most common
genetic alterations present in lung cancer. Approximately
70% of small cell lung cancer cell lines and 50% of non-small
cell lung cancer (NSCLC) cell lines harbor p53 mutations.5 In
contrast, p63 and p73 mutations occur rarely in cancer,2,6,7
supporting the recent hypothesis that altered N:TA expres-
sion ratio, rather than gene mutations, plays a role in cancer
pathogenesis. Gene expression de-regulation of both p63 and
p73 N-terminal isoforms is commonly observed in bladder,
ovarian, breast, and colon cancers.8–11 In NSCLC, Np73
protein expression correlates with poor prognosis.12 Np63
overexpression, both at protein and messenger RNA (mRNA)
levels, has been frequently reported to be associated with
squamous histotype.13,14 Moreover, TAp73 up-modulation
has been reported after cell exposure to a large variety of
chemotherapeutic agents, and if its activity is blocked, an
enhancement of chemoresistance is observed.15 In this article,
we report quantitative evaluation of N-terminal p63 and p73
isoforms in tumor tissues and corresponding morphological
normal tissues, obtained from the same resected lobe in
patients with early stage NSCLC.
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PATIENTS AND METHODS
Patients and Samples
Primary tumor and paired corresponding normal lung
specimens of 46 consecutive NSCLC patients who underwent
radical surgery at the San Luigi Hospital, Division of Tho-
racic Surgery, between December 2003 and March 2004,
were analyzed. Median age of patients (34 men and 12
women) was 69 years (range 41–82 years), and none of them
received either preoperative or postoperative chemotherapy
or radio-therapy according to the institutional treatment pol-
icy for resectable rescue in those years. Histological exami-
nation was performed on formalin-fixed tissue in all cases,
and tumors were diagnosed according to World Health Or-
ganization classification,16 including 26 adenocarcinomas, 17
squamous cell carcinomas, and 3 large cell carcinomas.
Differentiation grade (grade 1: 9, grade 2: 18, and grade 3: 19
cases), pT status (pT1: 10, pT2: 33, pT3: 2, and pT4: 1 cases),
and pN status (pN0: 32, pN1: 8, and pN2: 6 cases) were also
recorded. According to the tumor, node, metastasis classifi-
cation for solid tumors,17 29 cases resulted to be pathological
stage I, 10 stage II, and 7 stage III. Follow-up was available
in all cases. Informed consent was obtained from each pa-
tient, and the study was approved by the institutional review
board of the San Luigi Hospital. All samples were deidenti-
fied and cases anonymized by a staff member not involved in
the study. Clinical data were compared and analyzed through
coded data.
RNA Extraction, Complementary DNA
Synthesis, and Quantitative Polymerase Chain
Reaction
Total RNA (totRNA) was isolated from all tissue spec-
imens with the RNeasy 96 Kit and Biorobot 8000 (Qiagen,
Hilden, Germany) according to the manufacturer’s instruc-
tions. RNA was extracted from 15 to 25 mg and 60 to 80 mg
of tumor and normal lung tissues specimens, respectively.
Genomic DNA contamination was removed by on-column-
DNAseI treatment (Qiagen). totRNA was then quantified
with an Agilent 2100 Bioanalyzer (Agilent Technologies,
Palo Alto, CA) and stored at 80°C. Two micrograms of
totRNA were finally retrotranscribed with random hexamer
primers and Multiscribe Reverse transcription contained in
the High Capacity complementary DNA Archive Kit (Ap-
plied Biosystems, Foster City, CA), in accordance with man-
ufacturer’s suggestions.
Expression levels of all target genes and ß-actin
reference gene were evaluated with SYBR green (Applied
Biosystems) technology with optimized polymerase chain
reaction (PCR) condition and primer concentrations.
Primer sequences were as follow: p53.FW:GCATTCTGG-
GACAGCCAAGT, p53.RW:CAGTTGGCAAAACATCT-
TGTTGA, p63.FW:GTCGAGCACCGCCAAGTC, p63.RW:
TGGCAGTAGAGTTTCTTCAGTTCAGT, p73.FW:CCAG-
CACGGCCAAGTCA, p73.RW:CTTGGCGATCTGGCAGTAG
AG, TAp63.FW:GGTTTTCCAGCATATCTGGGA, TAp63.
RW:CAAGTCAATGGGCTGAACTGA, DNp63.FW:GAAAA-
CAATGCCGAGACTCAATT, DNp63.RW:TGTTCAGGA-
GCCCCAGGTT, TAp73.FW:CGCCACCTCCCCTGATG,
TAp73.RW:GTCGAAGTAGGTGCTGTCTGGTT, Dex2p73
FW:GCTGCGACGGCTGCAGGG, Dex2p73.RW:TTCCGCCC-
ACCACCTCATTATTC, Dex2/ex3p73.FW:CGATGCCCGGG-
GCT, Dex2/ex3p73.RW:GCGCGGCTGCTCATCT, DNp73.FW:
CCACCTGGAGGGCATGACTA, DNp73.RW:CGCTTTTCCC-
ATCTCCCTTAG, DNp73.FW:CACGGCACCTCGCCAC,
DNp73.RW:ATCTGGTCCATGGTGCTGCT, ACTB.FW:
GAGTCCGGCCCCTCCAT, and ACTB.RW: GCAACTA-
AGTCATAGTCCGCCTAGA. Melting curve analysis was
performed for all the amplicons. Quantitative PCR was car-
ried out on an ABI PRISM 7900HT Sequence Detection
System (Applied Biosystems) in 384-wells plates assembled
by Biorobot 8000, and reactions were performed in a final
volume of 20 l. All quantitative PCR mixtures contained 1
l of complementary DNA template, 1 SYBR Universal
PCR Master Mix (2, Applied Biosystems). Cycle condi-
tions were as follows: after an initial 2-minute hold at 50°C
to allow AmpErase: UNG (Applied Biosystems) activity, and
10 minutes at 95°C, the samples were cycled 40 times at 95°C
for 15 seconds and 60°C for 1 minute. For 2/3p73 primers,
annealing time was reduced down to 30 seconds and temper-
ature was increased up to 65°C to obtain a specific amplicon.
Baseline and threshold for Ct calculation were set manually
with the ABI Prism SDS version 2.1 software (Applied
Biosystems).
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues were cut
into 4-m thick sections and collected onto charged slides for
immunohistochemical staining. After deparaffination and re-
hydration through graded alcohols and phosphate-buffered
saline (pH 7.5), the endogenous peroxidase activity was
blocked by incubation with absolute methanol and 0.3%
hydrogen peroxide for 15 minutes. Sections were incubated at
the optimal conditions with the following primary antibodies:
(1) mouse monoclonal antibody anti-ki67 (1:300; MIB-1,
DakoCytomation, Glostrup, Denmark); (2) rabbit polyclonal
p73 (1:500; AB14430, Abcam, Cambridge, UK) epitope
corresponding to the NH2-terminal region (this antibody
recognizes the TAp73 isoforms but does not detect the
Np73 variant or p53); (3) mouse monoclonal Np73 (1:
500; AB13649, Abcam, Cambridge, UK) developed against a
peptide corresponding to amino acids 2 to 13 of human
Np73 (LYVGDPARHLAT), and this antibody does not
cross react with any TAp73 isoforms or p53; (4) goat poly-
clonal ab TA*p63 (1:100; sc-7254, Santa Cruz, CA); and (5)
mouse monoclonal Np63 (1:800; p40, Zymed Laboratories,
San Francisco, CA). Immunoreaction was revealed by a
dextran-chain (biotin-free) detection system (EnVision; Da-
koCytomation), using 3,3-diaminobenzidine (DakoCytoma-
tion) as a chromogen. The sections were lightly counter-
stained with hematoxylin. Negative control reactions were
obtained by omitting the primary antibody. ki67 proliferation
index was calculated as the percentage of positive nuclei
among at least 200 nuclei counted at high magnification in the
areas of highest labeling.
Lo Iacono et al. Journal of Thoracic Oncology • Volume 6, Number 3, March 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer474
Statistical Analysis
Isoform expression levels have been dichotomized into
two groups of “high” and “low” expression using k-means
algorithm and median cutoff for transcripts and protein ex-
pression, respectively. For each isoform, staining intensity
and percentage of cells with nuclear and cytoplasmic expres-
sion were evaluated. Significant associations between pa-
tients’ clinicopathological features and both transcript and
protein expression levels were evaluated by the Pearson’s 2
test with Yates’ continuity correction. Differential transcript
expression between tumor and corresponding normal tissue
samples were evaluated using t test for paired data. Using a
threshold of Ct1 (fold change2), the expression ratios
of N-terminal isoforms between tumor/normal tissues were
clustered into three groups (up-regulation, down-regulation,
or not regulated), and the association with clinicopathological
variables was evaluated using the Kruskal-Wallis test.
Kaplan-Meier plots and Log-rank tests were used for survival
analysis. Overall survival time was calculated from the date
of surgery to death or last follow-up date. Cox regression was
used in the univariate survival analysis to determine the
association of N-terminal isoform expression or tumor mod-
ulation with overall survival. All significant associations with
p 0.05 were subsequently subjected to the multivariate Cox
regression analysis to determine the hazard ratios (HRs) and
the independence of effects. Statistical analysis was per-
formed using R statistical software (R Foundation for Statis-
tical Computing, http://www.r-project.org/foundation/).18
RESULTS
In both tumor and paired morphological normal lung
samples, p53 gene showed the highest transcript level and
p73 the lowest (Figure 1A). In terms of N-terminal isoforms
TAp63, TAp73, and Np73 were highly expressed, whereas
Np73 had the lowest transcript levels (Figures 1B, C).
FIGURE 1. p53 family members
transcripts expression levels in non-
small cell lung cancer (NSCLC) pa-
tients tissues. Box plot diagrams
showing the normalized expression
levels Ct (CtTarget  Ctreference) of
p53 family members in 46 NSCLC
and paired nontumoral tissues. A,
p53, p63 and p73 expression levels.
B, p63 N-terminal isoforms expres-
sion levels. C, p73 N-terminal iso-
forms expression levels. The line
within the boxes indicates the me-
dian expression level. The top edge
of the boxes represents the 75th,
and the bottom edge represents the
25th percentile. The range is shown
as a vertical edge.
FIGURE 2. p63 and p73 N-terminal isoforms expression pattern in non-small cell lung cancer (NSCLC) patients. Modulations
of p63 and p73 N-terminal isoforms were analyzed with paired t test, and **p  0.05 and ***p  0.01 are found to be signifi-
cant. Black arrows indicate the direction of N-terminal isoforms modulation in tumors. 2p73, 2/3p73, and Np63 tran-
scripts were significantly up-modulated, whereas TAp63, Np73, and Np73 isoforms were down-modulated in NSCLC.
Solid block shows general expression level of p53 family members, whereas dotted blocks indicate gene-specific N-terminal
isoforms. The filled lines correspond to a cutoff of 2-fold change (CT 1).
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Modulation of p63/p73 N-terminal isoforms was eval-
uated comparing expression in tumoral versus matched nor-
mal tissue (Figure 2). No difference in p63 and p73 mRNA
expression was detected when whole transcript amplicons
were evaluated. By contrast, when N-terminal isoforms were
analyzed, Np63 was significantly up-modulated (p  0.02),
whereas TAp63 was slightly down-modulated (p  0.01).
Likewise, 2p73 and 2/3p73 were up-modulated (all p 
0.001), whereas Np73 and Np73 isoforms were down-
modulated (all p  0.001). These results suggest a complex
TP63 and TP73 gene expression tuning in N-terminal iso-
forms modulation in NSCLC.
Correlations between p63/p73 N-terminal isoform tran-
scripts levels and clinicopathological features were evaluated
dichotomizing the results obtained in tumor specimens, in
“high” and “low” expression, according to Ct levels. More-
over, clinicopathological variables were also correlated to
p63 and p73 transcript modulation clustering tumors in up-
regulated, down-regulated, and not-regulated, according to
their Ct levels using a cutoff Ct 1 (corresponding to
fold change 2). These results are summarized in Table 1.
High p63 transcript levels in tumor specimens and p63
up-modulation were observed in elderly patients (p  0.002
and p  0.02, respectively, Table 1), and this correlation was
also confirmed for Np63 (p  0.04, Table 1). Moreover,
tumor grade II and III showed a significantly higher Np63
expression (p  0.04, Table 1). For both p63 and p73, a
significant association was found with squamous histotype
(all p  0.01, Table 1). Indeed, Np63 was highly expressed
and significantly up-modulated in squamous histotype and
TABLE 1. Relationships between p63-p73 Expression Levels
and ki67, or Clinicopathologic Characteristics, in 46 Lung
Cancer Patients’ Specimens
Age
Expression Index Modulation Index
High Low High Low
p  0.002 p  0.02
p63 High 12 4 UP 12 8
NR 3 6
Low 7 23 DW 4 13
p  0.04
Np63 High 15 12
Low 4 15
Grade
Expression Index
I II III
p  0.04
p63 High 0 9 7
Low 9 9 12
p  0.04
Np63 High 2 13 12
Low 7 5 7
Diagnosis
Expression Index Modulation Index
non-
SQCA SQCA
non
SQCA SQCA
p  0.00002 p  1.12 10-5
p63 High 3 13 UP 5 15
NR 8 1
Low 26 4 DW 16 1
p  0.03
TAp63 High 4 8
Low 25 9
p  0.0006 p  1 10-5
Np63 High 11 16 UP 6 16
NR 7 0
Low 18 1 DW 16 1
p  0.01 p  7 10-5
p73 High 10 13 UP 8 15
NR 10 2
Low 19 4 DW 11 0
p  0.009
TAp73 High 11 14
Low 18 3
p  0.01
2p73 UP 12 14
NR 14 2
DW 3 1
(Continued)
TABLE 1. (Continued)
ki67
Expression Index Modulation Index
Low High Low High
p  0.0006 p  0.0005
p63 High 2 14 UP 4 16
NR 6 3
Low 21 9 DW 13 4
p  0.016 p  0.002
Np63 High 4 19 UP 5 17
NR 6 1
Low 19 4 DW 12 5
p  4 10-5 p  0.001
p73 High 3 9 UP 6 17
NR 8 4
Low 20 14 DW 9 2
p  0.003
TAp73 High 7 18
Low 16 5
p  0.01 p  0.07
2p73 High 8 17 UP 16 10
NR 6 10
Low 15 6 DW 1 3
SQCA, squamous cell carcinoma; UP, up-regulated; NR, not regulated; DW,
down-regulated.
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2p73 (p  0.01, Table 1). Furthermore, TAp73 expression
was significantly higher in squamous tumors, whereas TAp63
level was lower in nonsquamous histotype (p  0.009 and
p 0.03, respectively, Table 1). Considering proproliferative
and antiproliferative activity of both p63 and p73 isoforms,
we also evaluated the correlation among isoform expression
levels and proliferation marker ki67. Tumor with high pro-
liferative rate showed high levels of TAp73, Np63, and
2p73 isoforms (all p  0.01, Table 1). To corroborate the
transcript analysis data, 29 NSCLC samples were evaluated
by immunohistochemistry with N-terminal p63/p73 isoforms
commercial antibodies. TAp63, Np63, TAp73, and Np73
immunoreactivity was observed in 89, 41, 93, and 48% lung
cancer specimens, respectively (Figure 3). Immunohisto-
chemistry analysis revealed that only TAp73 isoforms was
localized in both nuclear and cytoplasmic compartment. No
correlation was identified among TAp73 protein and TAp73
transcript, although a trend was observed between nuclear
TAp73 staining and 2p73 mRNA expression in NSCLC
(p  0.08). TAp63 and Np73 decorated the nuclear and the
cytoplasmic compartment, respectively. No concordance with
transcript analysis was observed. Np63 protein isoform was
localized at the nuclear level correlating with Np63 mRNA
expression in tumor samples (p  0.01). No correlation was
observed between the patient’s clinicophatological features
and either the p63 or p73 protein expression. The association
previously identified between Np63 mRNA expression and
both the patient’s diagnosis age and the squamous histotype
was also confirmed for Np63 protein isoform (p  0.04,
p  0.01, respectively).
Neither transcript expression level nor gene modulation
of both p63 and p73 N-terminal isoforms were significantly
associated with survival in the overall cohort of NSCLC
patients. However, in nonsquamous carcinoma patients, high
expression of 2p73 transcript and TAp73 protein was asso-
ciated with an unfavorable outcome (p 0.009 and p 0.03,
respectively; Figure 4, upper panel). Moreover, in nonsqua-
mous tumors, down-modulation of TAp63, Np63, and
Np73 were significantly associated with poor patients’
survival (p  0.005, p  0.03, and p  0.04, respectively;
Figure 4, lower panel). Interestingly, TAp63 and Np73
transcript expression levels had prognostic relevance also
when their expression was evaluated in morphologically
normal lung tissue. Indeed, high transcript levels of TAp63
and Np73 were significantly correlated with adverse prog-
nosis (p 0.002 and p 0.005, respectively, Figure 5, upper
panel), and the prognostic significance was even more statis-
tically significant when patients were stratified according to
tumor histotype (Figure 5, lower panel). Multivariate analy-
ses showed that Np73 (p  0.049, HR  3.091, 95%
confidence interval  1.005–9.524) and TAp63 (p  0.001,
HR  8.091, 95% confidence interval  2.254–29.05) in
morphological normal tissues were independent prognostic
factors of overall survival.
DISCUSSION
The results of our research support the hypothesis that
altered N:TA expression ratio for p63 and p73 genes, rather
than single isoform deregulation, could play a role in cancer
pathogenesis.19,20 Indeed, both p63 and p73 genes showed no
differential expression between tumor and corresponding normal
lung tissue when transcript expression levels were measured
using amplicons generated from all N-terminal isoforms. Con-
versely, the assessment of specific N-terminal isoforms revealed
that Np63 was overexpressed, whereas TAp63 was reduced.
Similarly, for p73 gene, up-modulation of both 2p73 and
2/3p73 and down-modulation of Np73 and Np73 isoforms
FIGURE 3. Immunohistochemical detection of N-terminal p63/p73 isoforms in lung cancer. Tumor samples with “low” (A, C,
E, and G) and “high” N-terminal isoforms expression (B, D, F, and H). Both p63 N-terminal isoforms were predominantly ex-
pressed in nuclear compartment (B and D, respectively). TAp73 isoforms (TAp73, 2p73) localized in both nuclear and cyto-
plasmic compartment (F), whereas Np73 was chiefly expressed in cytoplasm (H). Original magnification, 200.
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were observed, whereas TAp73 level remained unchanged.
Therefore, it seems that in NSCLC, an isoform shift might
occur, which promotes expression of p63 and p73 antiapoptotic
isoforms, suggesting an etiological role of p73/p63 in lung
carcinogenesis and tumor proliferation. In support of this hy-
pothesis, we identified a correlation between high proliferative
tumor index and increased mRNA expression level of TAp73,
2p73, and Np63 isoforms (Table 1). Since most of the p73
N-terminal isoforms showing opposite regulation are generated
by alternative splicing, the p73 gene modulation observed in our
cohort suggest a tampered splicing process that has recently
linked to a variety of human cancers.21 Moreover, in transgenic
mouse model of hepatocarcinogenesis, a 2/3p73 oncogenic
potential has already been documented.22 At the protein level,
FIGURE 4. Expression level/modulation of p63 and p73 N-terminal isoforms affect nonsquamous non-small cell lung cancer
patients survival. For each isoform, transcript/protein expression levels have been dichotomized into two groups of “high”
(filled line) and “low” (dotted line) expression using k-means/median value, and Kaplan–Meier analysis was carried out on the
two groups. In nonsquamous cell carcinoma tumors, the high 2p73 transcript/protein expression was associated to unfavor-
able outcome (p  0.01 and p  0.03, respectively, upper panel). Transcript modulation: p63 and p73 N-terminal isoforms
expression levels were clustered into three groups: up-regulation, down-regulation, or not regulated. Regulated according to
their fold change using log2(FC) 1 as threshold. Kaplan–Meier analysis showed that TAp63, Np63, and Np73 down-
modulations were correlated with poor patients survival (p  0.01, p  0.03, and p  0.04, respectively, lower panel).
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FIGURE 5. In morphological normal lung specimens, TAp63 and Np73 gene expression levels correlate with poor patients
survival. For each isoform, transcript/protein expression levels have been dichotomized into two groups of “high” (filled line)
and “low” (dotted line) expression using k-means/median value, and Kaplan–Meier analysis was carried out on the two
groups. In the whole patients cohort of morphological normal lung specimens, the high TAp63 and Np73 expression levels
correlate with poor prognosis (upper panel). Statistical relevance of this analysis increases when patients with squamous carci-
noma were excluded (lower panel).
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NSCLC tumors express TAp73 N-terminal isoforms, but p73
commercial antibody directed against N-terminal epitope cannot
distinguish among the various TAp73 isoforms (TAp73, 2p73)
and cannot recognize the isoform coding by2/3p73. According
to literature, TAp73 protein staining (2p73 and TAp73) were
observed in both cytoplasmic and nuclear subcellular compart-
ments, whereas the Np73 isoform was expressed predomi-
nantly in cytoplasm.12,23 This difference in the subcellular local-
ization of the p73 N-terminal isoforms further complicates the
fine tuning of the N:TA ratio, and highlights the existence of a
nuclear import/export mechanism24 that could be de-regulated
by tumor.
Neither transcript expression level nor gene modulation
of both p63 and p73 N-terminal isoforms were significantly
associated with survival in the overall cohort of NSCLC
patients. However, in nonsquamous carcinoma patients,
down-modulation of Np73 and TAp63 isoforms were cor-
related with poor prognosis. Conversely, a prognostic role of
high transcript levels of these isoforms in morphologically
normal lung tissue was documented, suggesting a potential
role of Np73 and TAp63 isoform transcripts analysis for
the detection of subjects at higher lung cancer risk. Intrigu-
ingly, in H1299 lung carcinoma cell line, the expression of
Np73ß isoform led to genomic instability.25 In nonsqua-
mous tumors, a poor patient survival correlate to 2p73 high
transcript level and to TAp73 nuclear staining and (p 0.01
and p  0.03, respectively). It is likely that the TAp73
nuclear staining is predominantly generated by 2p73 tran-
script because the antibody used cannot discriminate between
TAp73 and 2p73 proteins, and a trend between nuclear
TAp73 staining and 2p73 mRNA expression in NSCLC
(p 0.08) was observed. These results could also suggest the
use of this antibody to better stratify nonsquamous carcinoma
patients. Our results highlight the importance of identifying
new molecular markers to improve tumor subtype definition.
The discrepancy in survival analysis observed between squa-
mous and nonsquamous histotypes could result from molec-
ular differences of these tumors subtypes. The higher Np63
transcript and protein levels detected in squamous versus
nonsquamous (medium fold change 33 and 0.4, respectively)
could be due to 3q amplification, which is a common molec-
ular alteration in squamous cell lung cancer.13 These molec-
ular differences could entail different responsiveness to che-
motherapy. Indeed, coexpression of high mRNA levels in
squamous histotype of both Np63 and TAp73 is particularly
intriguing because a cross-talk between these isoforms has been
recently reported and correlated with the sensitivity to cisplatin.
It has been found that Np63 is an essential survival factor in
head and neck squamous cell carcinoma through its ability to
suppress p73-dependent apoptosis and that loss of TAp73 activ-
ity attenuated cellular sensitivity to cisplatin,26 which is a back-
bone agent for systemic therapy for NSCLC. Moreover, in
triple-negative primary breast carcinoma, it has been shown that
platinum-triggered apoptosis requires the dissociation of
Np63/TAp73 complex mediated by c-ABL-dependent phos-
phorylation of TAp73.27 Therefore, further studies in NSCLC
platinum-treated patients are worth of consideration to explore if
N:TA ratio may be a useful predictive marker of a differential
sensitivity to platinum compounds.
In conclusion, our findings suggest that p63 and p73
altered N:TA expression ratio occurs in NSCLC and could
contribute to the molecular pathogenesis/aggressiveness of
NSCLC tumors. Future studies on the fine regulation of both p63
and p73 N-terminal isoforms and their potential role in the
different lung cancer subtypes could be helpful for further
understanding neoplastic transformation of lung epithelium, sug-
gesting new pathways to develop future personalized therapy.
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